AUS
NZ
UK
CA
USA
IND
_06_16_2026_06_12_08_773360.jpg)
Performance of the Healthcare sector in the UK
The United Kingdom is the host to one of the worldâs strongest and most productive health care sector and is ranked number one globally in production, development and commercialisation of clinical products such as medicines. There are over 5,600 healthcare and life sciences organisations operating in the United Kingdom. One of the global market leaders and the worldâs fastest-growing pharmaceutical companies GlaxoSmithKline is also running its operations from the United Kingdom. The healthcare business in the UK currently boasts of a yearly turnover of over £70 billion. Around £30 billion of this is made up from global supply, which means that the interest towards the British life sciences products and ventures keeps on flourishing. Healthcare and Lifesciences organisations who have picked Britain for their operations realised that they have many monetary benefits and many funding opportunities in the nation. The UK is also a global thought leader when it comes to healthcare publishing, it has the highest per capita share of the top 1 per cent highest cited life sciences publications worldwide and is second only to the United States of America in terms of gross share. Post the uncertainties around the Geopolitical situations such as Brexit is done with, the country is expected to receive a large inflow of capital and investment within this industry because of its ever-growing nature.
Primary Health Properties Plc
Primary Health Properties Plc (LON: PHP) is a London, United Kingdom based organisation that operates primarily as a Real Estate Investment Trust (REIT) by making investments into healthcare providing facilities and properties. The list of the companyâs core services includes Acquisition and Development of properties across the United Kingdom, Property Management of healthcare facilities, Landlord and Tenant, Asset Management for the purpose of Lease Renewals, Property Refurbishments, Building extensions as well as management of renewable projects and providing support in terms of all kinds of financial situations such as rent collection, service charges, and payment of invoices. The company has an occupancy of 99.5 per cent across all its properties and its portfolio includes some of the best healthcare and primary care facilities across the country such as Mountain Ash Primary Care Centre, The Meath Primary Care Centre, Kew Medical Centre in Emerald Gardens as well as Oakwood Lane Medical Centre in Yorkshire and many more.
PHP Share Price Performance
(Source: Thomson Reuters) Daily Chart as on 18-December-19, before the close of the market
As on 18th December 2019, at 08:30 A.M Greenwich Mean Time, while writing, Primary Health Properties Plcâs price of the share was reported at GBX 152.40 per share on the London Stock Exchange, a decline in the value of 0.78 per cent or GBX 1.20 per share, as opposed to the last dayâs closing price, which was reported at GBX 153.60 per share. The companyâs market capitalisation stood at a value of GBP 1.868 billion in relation with the present market price of the share of the company.
Companyâs share beta was reported to be at a value of 0.22; it means that the movement of the share of Primary Health Properties Plc, has been less volatile, in comparison with the movement of the comparative benchmark index in the last one year.
ImmuPharma Plc
ImmuPharma Plc (LON: IMM) is a London, the United Kingdom based healthcare organisation which primarily operates as a Pharmaceuticals and Biotechnology company, engaged in the business of research, development as well as commercialisation of novelty drugs for the treatment of conditions with unmet need. The company has a focus on the treatment in three core areas which are Auto-immune diseases, Oncology as well as Metabolism or Diabetes. The companyâs flagship drug is Lupuzorâ¢, which has been developed to counter a life-threatening disease Lupus, which is a part of the core Auto-Immune area. Lupuzorâs⢠Phase III trial has been completed successfully, and the drug also received a Gold Standard approval from the United States Food and Drugs Administration (FDA).
IMM Share Price Performance
(Source: Thomson Reuters) Daily Chart as on 18-December-19, before the close of the market
As on 18th December 2019, at 08:35 A.M Greenwich Mean Time, while writing, ImmuPharma Plcâs price of the share was at GBX 16.75 per share on the London Stock Exchange, an increase in the value of 0.90 per cent or GBX 0.15 per share, as opposed to the last dayâs closing price, which was reported at GBX 16.60 per share. The companyâs market capitalisation stood at a value of GBP 27.78 million in relation to the present market price of the share of the company.
Companyâs share beta was reported to be at a value of -0.07; it means that the movement of the share of ImmuPharma Plc, has been less volatile and inverse, in comparison with the movement of the comparative benchmark index in the last one year.
Mediclinic International Plc
Mediclinic International Plc (LON: MDC) is a London, the United Kingdom based Healthcare Equipment and Services providing organisation. The company is focused on providing specialist services in the healthcare sector for the patients, medical practitioners, funders and regulators of healthcare. The company has three primary business divisions which are Mediclinic Middle East, Hislanden, Switzerland and Mediclinic Southern Africa. It has also made a special investment in the Spire Healthcare group in the United Kingdom. The group currently operates through a host of 77 Hospitals and 5 Sub-acute hospitals as well as 13 Day clinics and 22 Outpatient clinics. The company provides 11,359 Inpatient beds with 750000 inpatient admissions.
MDC Share Price Performance
(Source: Thomson Reuters) Daily Chart as on 18-December-19, before the close of the market
As on 18th December 2019, at 08:40 A.M Greenwich Mean Time, while writing, Mediclinic International Plcâs price of the share was reported at GBX 396.20 per share on the London Stock Exchange, an increase in the value of 0.15 per cent or GBX 0.60 per share, as opposed to the last dayâs closing price, which was reported at GBX 395.60 per share. The companyâs market capitalisation stood at a value of GBP 2.916 billion in relation to the present market price of the share of the company.
Companyâs share beta was reported to be at a value of 1.32; it means that the movement of the share of Mediclinic International Plc, has been more volatile, in comparison with the movement of the comparative benchmark index in the last one year.
NMC Health Plc
NMC Health Plc (LON: NMC) is the most significant healthcare company in the Gulf Cooperation Council (GCC) and is listed on the main market of the London Share Exchange. The healthcare group has an international network of healthcare facilities across 19 countries. NMC Health Plc is also one of the major players in the global markets of In-Vitro Fertilisation (IVF) and through its subsidiary ProVita, is regarded as one of the major providers of long-term medical care in the UAE. Comprising a global footprint following aggressive expansion programs post-2016, the group has a total capacity of 3,109 beds across 19 countries, and around 48% of the groupâs total capacity now is in Kingdom of Saudi Arabia (KSA). It is also a major supplier of healthcare equipment, products and consumables across several core market segments, with a significant share of revenues coming from the healthcare-related products.
NMC Share Price Performance
(Source: Thomson Reuters) Daily Chart as on 18-December-19, before the close of the market
As on 18th December 2019, at 08:40 A.M Greenwich Mean Time, while writing, NMC Health Plcâs price of the share was reported at GBX 1769.00 per share on the London Stock Exchange, an increase in the value of 1.23 per cent or GBX 21.50 per share, as opposed to the last dayâs closing price, which was reported at GBX 1747.50 per share. The companyâs market capitalisation stood at a value of GBP 3.650 billion in relation to the present market price of the share of the company.
Companyâs share beta was reported to be at a value of 0.75; it means that the movement of the share of NMC Health Plc, has been less volatile, in comparison with the movement of the comparative benchmark index in the last one year.
